Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 2/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.47 |
| ▸ | ADORA1 | P30542 | 7/20 | 0.45 |
| ▸ | ADORA2A | P29274 | 6/20 | 0.45 |
| ▸ | ADORA3 | P0DMS8 | 4/20 | 0.45 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.45 |
| ▸ | JAK3 | P52333 | 1/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.45 |
| ▸ | ESR1 | P03372 | 1/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | HPGD | P15428 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.42 |
| ▸ | KDR | P35968 | 1/20 | 0.42 |
| ▸ | GSK3B | P49841 | 1/20 | 0.42 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3163125 | 1.00 | NPC1 (0.47) | NPC1ALDH1A1ADORA1ADORA2AADORA3 | |
| SCHEMBL3260230 | 0.92 | ADORA3 (0.46) | ALDH1A1ADORA1ADORA2AADORA3ADORA2B | |
| SCHEMBL3171920 | 0.91 | ADORA1 (0.47) | ALDH1A1ADORA1ADORA2AADORA3ADORA2B | |
| SCHEMBL3156207 | 0.91 | ALDH1A1 (0.48) | ALDH1A1ADORA1ADORA2AADORA3ADORA2B | |
| SCHEMBL3163144 | 0.90 | ADORA3 (0.46) | ALDH1A1ADORA1ADORA2AADORA3ADORA2B | |
| SCHEMBL3164858 | 0.90 | ALDH1A1 (0.49) | NPC1ALDH1A1ADORA1ADORA2AJAK3 | |
| SCHEMBL3175543 | 0.90 | EGFR (0.50) | ALDH1A1JAK3KDM4EMEN1MAPT | |
| SCHEMBL3171949 | 0.90 | PARP1 (0.47) | ALDH1A1ADORA1ADORA2AADORA3ADORA2B | |
| SCHEMBL3163746 | 0.89 | ALDH1A1 (0.50) | ALDH1A1ADORA1ADORA2AADORA3ADORA2B | |
| SCHEMBL3162425 | 0.89 | EGFR (0.53) | ALDH1A1JAK3KDM4EMEN1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1465631-B1 | PYRIMIDINE A2B SELECTIVE ANTAGONIST COMPOUNDS, THEIR SYNTHESIS AND USE | OSI PHARM INC (US) | 2010-02-24 | — | — | EP | disclosed |
| US-6916804-B2 | Pyrimidine A2b selective antagonist compounds, their synthesis and use | OSI PHARMACEUTICALS, INC. (US) | 2005-07-12 | — | — | US | disclosed |
| EP-1465631-A4 | PYRIMIDINE A2B SELECTIVE ANTAGONIST COMPOUNDS, THEIR SYNTHESIS AND USE | OSI PHARM INC (US) | 2005-03-30 | — | — | EP | disclosed |
| EP-1465631-A2 | PYRIMIDINE A2B SELECTIVE ANTAGONIST COMPOUNDS, THEIR SYNTHESIS AND USE | OSI Pharmaceuticals, Inc. (US) | 2004-10-13 | — | — | EP | disclosed |
| US-20030162764-A1 | Pyrimidine A2b selective antagonist compounds, their synthesis and use | OSI PHARMACEUTICALS, INC. | 2003-08-28 | — | — | US | disclosed |
| WO-2003053366-A2 | PYRIMIDINE A2B SELECTIVE ANTAGONIST COMPOUNDS, THEIR SYNTHESIS AND USE | OSI PHARMACEUTICALS, INC. (US) | 2003-07-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030162764-A1 | Pyrimidine A2b selective antagonist compounds, their synthesis and use | ADORA2B, ADORA2A, ADORA3 | NPC1 981/4885ALDH1A1 1491/4885ADORA1 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.